Sacituzumab Govitecan (SG) + Topotecan + Amrubicin (Japan only)
Phase 3Recruiting 3 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Trial Timeline
Apr 4, 2025 → Oct 1, 2029
NCT ID
NCT06801834About Sacituzumab Govitecan (SG) + Topotecan + Amrubicin (Japan only)
Sacituzumab Govitecan (SG) + Topotecan + Amrubicin (Japan only) is a phase 3 stage product being developed by Gilead Sciences for Extensive Stage Small Cell Lung Cancer (ES-SCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06801834. Target conditions include Extensive Stage Small Cell Lung Cancer (ES-SCLC).
What happened to similar drugs?
0 of 10 similar drugs in Extensive Stage Small Cell Lung Cancer (ES-SCLC) were approved
Approved (0) Terminated (1) Active (9)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06801834 | Phase 3 | Recruiting |
Competing Products
20 competing products in Extensive Stage Small Cell Lung Cancer (ES-SCLC)